Opsumit (Macitentan)

Macitentan, the active ingredient in Opsumit, is a endothelin receptor antagonist presented as a tablet for oral use. It is indicated for the treatment of pulmonary arterial hypertension in adults. GNH USA supplies Opsumit as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Opsumit as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Opsumit is an endothelin receptor antagonist used in the management of pulmonary arterial hypertension, a disease affecting the pulmonary vascular endothelium. - Pulmonary arterial hypertension (PAH): Improves exercise capacity and delays disease progression. - WHO Group 1 PAH: Reduces risk of clinical worsening. - Chronic thromboembolic pulmonary hypertension (CTEPH) after surgical evaluation: Supports long‑term management.

Common Side Effects: - Headache - Nasopharyngitis - Peripheral edema - Fatigue - Upper respiratory tract infection - Dizziness

Serious or Rare Side Effects: - Liver enzyme elevation - Anemia - Pulmonary edema - Severe hypotension - Drug‑induced hepatitis - Embryonic toxicity (risk to fetus).

Patients should be evaluated before initiating therapy and monitored regularly throughout treatment. - Baseline liver function tests: Perform before starting and periodically during therapy. - Hemoglobin monitoring: Check periodically for anemia. - Pregnancy avoidance: Effective contraception required for women of childbearing potential. - Drug interactions: Review concomitant medications for potential interactions. - Renal impairment: Use with caution in patients with reduced kidney function. - Store at below 25°C: Keep in the original packaging, protect from moisture.

Macrom  

---

---